Changes in Body Composition with Ritonavir-Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96-Week Randomized, Controlled Study
Changes in Body Composition with Ritonavir-Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96-Week Randomized, Controlled Study
复制标题
DOI：
10.1086/597776
复制
发表时间：
2009-05-01
影响因子：
11.8
通讯作者：
McGrath, Donnie
中科院分区：
文献类型：
--
作者：
McComsey, Grace;Rightmire, Anna;McGrath, Donnie
这项为期96周的开放标签随机研究评估了阿扎那韦或利托那韦增强阿扎那韦联合司他夫定和拉米夫定治疗的1型人类免疫缺陷病毒感染患者体内成分的变化。两个治疗组躯干脂肪的增加相似，但接受利托那韦增强的阿扎那韦治疗的患者脂肪萎缩的发生率显著降低。
This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine. Both treatment groups had similar increases in trunk fat, but patients treated with ritonavir-boosted atazanavir had a significantly lower incidence of lipoatrophy.